Teleflex (TFX) announced it has entered into definitive agreements to sell the company’s Acute Care, Interventional Urology and OEM businesses to two buyers, Intersurgical with respect to Acute Care and Interventional Urology, and Montagu and Kohlberg with respect to OEM, for a combined total of $2.03 billion in cash, subject to certain closing adjustments.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TFX:
- Teleflex’s Strategic Sale and Uncertain Valuation Lead to Sell Rating
- Optimistic Buy Rating for Teleflex Driven by Strong Vascular Business Growth and Strategic Innovations
- Teleflex price target lowered to $120 from $135 at RBC Capital
- Teleflex Reports Strong Revenue Growth Amid Challenges
- Teleflex’s Earnings Call: Growth Amid Challenges